A Phase II Study of Letrozole with or without PD 0332991 as First-Line Therapy for Advanced Breast Cancer


A Phase II Study of Letrozole with or without PD 0332991 as First-Line Therapy for Advanced Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Rowan T Chlebowski, MD, PhD (1/9/13) and Clifford Hudis, MD (1/11/13)
Finn RS et al. Results of a randomized Phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER-positive/HER2-negative advanced breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract S1-6.

Dr Chlebowski is Professor of Medicine at David Geffen School of Medicine at UCLA and Chief of the Division of Medical Oncology and Hematology at Harbor-UCLA Medical Center in Torrance, California.

Dr Hudis is Chief of the Breast Cancer Service in the Department of Medicine’s Solid Tumor Division at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York, New York.